Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic …
R Noviyani, S Youngkong, S Nathisuwan… - BMJ Evidence-Based …, 2022 - ebm.bmj.com
Objectives To assess cost-effectiveness of direct oral anticoagulants (DOACs) compared
with vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF) by pooling …
with vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF) by pooling …
Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
LA de Jong, J Groeneveld, J Stevanovic, H Rila… - PLoS …, 2019 - journals.plos.org
Introduction Randomized clinical trials (RCTs) and real-world data (RWD) in patients with
atrial fibrillation have shown that—compared to vitamin K antagonists (VKAs)—non-VKA oral …
atrial fibrillation have shown that—compared to vitamin K antagonists (VKAs)—non-VKA oral …
Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings
TI Verhoef, WK Redekop, F Hasrat, A de Boer… - American Journal of …, 2014 - Springer
Objectives Our objectives were to investigate the cost effectiveness of apixaban,
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …
A real-world observational study of hospitalization and health care costs among nonvalvular atrial fibrillation patients prescribed oral anticoagulants in the US …
A Amin, A Keshishian, J Trocio, O Dina, H Le… - Journal of Managed …, 2018 - jmcp.org
This article has been corrected. Please see J Manag Care Spec Pharm, 2020; 26 (5): 682
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …
Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control
A Janzic, M Kos - Pharmacoeconomics, 2015 - Springer
Background Vitamin K antagonists, such as warfarin, are standard treatments for stroke
prophylaxis in patients with atrial fibrillation. Patient outcomes depend on quality of warfarin …
prophylaxis in patients with atrial fibrillation. Patient outcomes depend on quality of warfarin …
Effectiveness and safety of non‐vitamin K antagonist oral anticoagulants in patients with non‐valvular atrial fibrillation: A nationwide, population‐based study in Korea
Background To compare the risk of stroke/systemic embolism (S/SE) and major bleeding
(MB) between non‐vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial …
(MB) between non‐vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial …
Outcomes after use of standard-and low-dose non–vitamin k oral anticoagulants in Asian patients with atrial fibrillation
MS Cho, JE Yun, JJ Park, YJ Kim, J Lee, H Kim… - Stroke, 2019 - Am Heart Assoc
Background and Purpose—Limited data are available describing the relative effectiveness,
safety, and optimal dosing of non–vitamin K antagonist oral anticoagulants (NOACs) for …
safety, and optimal dosing of non–vitamin K antagonist oral anticoagulants (NOACs) for …
A real-world observational study of hospitalization and health care costs among nonvalvular atrial fibrillation patients prescribed oral anticoagulants in the US …
A Amin, A Keshishian, J Trocio, O Dina, H Le… - Journal of managed …, 2020 - jmcp.org
This article has been corrected. Please see J Manag Care Spec Pharm, 2020; 26 (5): 682
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …
Methods for economic evaluations of novel oral anticoagulants in patients with atrial fibrillation: a systematic review
Y Li, P Chen, X Wang, Q Peng, S Xu, A Ma… - Applied Health Economics …, 2024 - Springer
Background Atrial fibrillation (AF) is a severe epidemiological and public health concern
among the elderly population worldwide, with substantial economic and social burdens …
among the elderly population worldwide, with substantial economic and social burdens …
Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of …
S Kohsaka, J Katada, K Saito, A Jenkins, B Li… - Open …, 2020 - openheart.bmj.com
Objective To assess the safety (ie, risk of bleeding) and effectiveness (ie, risk of
stroke/systemic embolism (SE)) separately for four non-vitamin K oral anticoagulants …
stroke/systemic embolism (SE)) separately for four non-vitamin K oral anticoagulants …